Aclaris Therapeutics, Inc.

As of June 30, 2026, Aclaris Therapeutics, Inc. carries a market capitalization of 735.38M, placing it among publicly traded companies globally. Its enterprise value stands at 643.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aclaris Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Aclaris Therapeutics, Inc. has 139.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 82.68, and the price-to-book ratio stands at 5.90.

These figures are as of June 30, 2026. The EV/Sales ratio of 78.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 643.82M versus a market cap of 735.38M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aclaris Therapeutics, Inc. maintains a current ratio of 3.46, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Aclaris Therapeutics, Inc. posted a negative return on equity (ROE) of -59.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -41.07, reflecting losses generated across the asset base. The company generates approximately 116,169.61 in revenue per employee across its workforce of 70.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Aclaris Therapeutics, Inc.'s stock has gained approximately 75.00% over the past 52 weeks. The 50-day moving average sits at 5.12, while the 200-day moving average is 4.45.

Over the twelve months ended June 30, 2026, Aclaris Therapeutics, Inc. generated 8.22M in revenue and converted that into -75.74M in net income, yielding earnings per share of -0.59. EBITDA reached -85.89M, while operating income came in at -85.51M.

These figures are as of June 30, 2026. Total book value stands at 124.58M, with working capital of 69.52M providing operational flexibility.

Aclaris Therapeutics, Inc. produced -62.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -118,000.00 in capital expenditures, free cash flow totaled -62.18M - equivalent to -0.48 per share.

Over the twelve months ended June 30, 2026, Aclaris Therapeutics, Inc. posted a gross margin of 12.90, reflecting its pricing power and cost economics. The operating margin of -1,040.43 and net profit margin of -921.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.11, meaning Aclaris Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Aclaris Therapeutics, Inc. has an Altman Z-Score of -0.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.